- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01020669
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development
Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior Development: Supplementary Control Subjects Recruitment
Background:
- Recent research has suggested that prenatal exposure to drugs may affect specific brain processes, including working memory, stress response, and decision making. However, most of the research on the effects of prenatal drug exposure in humans has been conducted early in life, and very little is known about effects of prenatal drug exposure during the crucial brain development period that takes place during puberty and adolescence. The biological and psychological changes associated with puberty may increase adolescents' sensitivity to prenatal substance exposure. Researchers are interested in using functional magnetic resonance imaging (fMRI) scans to study brain function and learn more about the effects of prenatal drug exposure on adolescents.
Objectives:
- To examine the effects of prenatal substance exposure on working memory, decision making, and normal brain activity in adolescents.
Eligibility:
- Adolescents between 12 and 17 years of age who are enrolled in a larger follow-up study of children exposed to drugs in utero.
Design:
- The study will involve a single outpatient session with two fMRI scans that will test working memory and decision-making processes.
- Participants will have brief medical history, a physical examination, and a urine test for drugs of abuse.
- Participants will then be trained on the working memory and decision-making tasks before having an initial MRI scan to provide a baseline reading.
- The fMRI scans will take 40 to 45 minutes each, and participants will have break in between as needed.
Study Overview
Status
Conditions
Detailed Description
Objective- To use fMRI to compare brain activity at rest and during working memory and decision making tasks in normal children and in children exposed in utero to drugs of abuse.
Study population- All participants will be 12-17 year-olds enrolled in an ongoing longitudinal follow up study of children exposed to drugs of abuse in utero funded by NIH. A subgroup of this study cohort will be invited to participate based on added criteria needed for scanning studies, such as absence of metal in the body, no significant CNS disease, and ability to tolerate the scanning environment.
Design- Participants will undergo fMRI scans while performing a working memory task, a decision making task and at rest. Data from participants in the current study will be combined with those from a previous study (NIDA protocol 417) which now reside in our repository protocol, 8002.
Outcome measures- The primary outcome measures will be the difference in BOLD fMRI activation between drug-exposed participants and those without prenatal exposure to drugs of abuse.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Maryland
-
Catonsville, Maryland, United States, 21228
- University of Maryland at Baltimore/MPRC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
INCLUSION CRITERIA:
- Participants must be enrolled in the current UMB longitudinal study protocol.
- All participants will be between 12 and 17 years old (inclusive).
- All participants must be able to provide informed assent and have a parent/guardian who can provide informed consent.
EXCLUSION CRITERIA:
- Report of a history of significant medical/neurological illness that might interfere with imaging data such as HIV positive status, cerebral vascular accident (CVA), central nervous system (CNS) tumor, head trauma, multiple sclerosis (MS) or other demyelinating diseases, epilepsy, or movement disorders.
- Metallic devices in the body that preclude MRI scanning, as determined by self and parent (guardian) report.
- Current use of psychotropic medication that may alter attentional functioning (e.g., Clonidine, antipsychotics, Effexor, stimulants).
- Currently using respiratory, cardiovascular, anticonvulsant or other medications that might interfere with the mechanisms producing the BOLD signal.
- Currently abusing street drugs as assessed by history and urine testing.
- Pregnancy, which will be assessed by history during screening and by urine testing on scan days.
- Claustrophobia by self and/or parent (guardian) report severe enough to preclude toleration of the scanning environment.
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Publications and helpful links
General Publications
- Accornero VH, Morrow CE, Bandstra ES, Johnson AL, Anthony JC. Behavioral outcome of preschoolers exposed prenatally to cocaine: role of maternal behavioral health. J Pediatr Psychol. 2002 Apr-May;27(3):259-69. doi: 10.1093/jpepsy/27.3.259.
- Bandstra ES, Morrow CE, Anthony JC, Accornero VH, Fried PA. Longitudinal investigation of task persistence and sustained attention in children with prenatal cocaine exposure. Neurotoxicol Teratol. 2001 Nov-Dec;23(6):545-59. doi: 10.1016/s0892-0362(01)00181-7.
- Ashtari M, Kumra S, Bhaskar SL, Clarke T, Thaden E, Cervellione KL, Rhinewine J, Kane JM, Adesman A, Milanaik R, Maytal J, Diamond A, Szeszko P, Ardekani BA. Attention-deficit/hyperactivity disorder: a preliminary diffusion tensor imaging study. Biol Psychiatry. 2005 Mar 1;57(5):448-55. doi: 10.1016/j.biopsych.2004.11.047.
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 999910455
- 10-DA-N455
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug Abuse
-
Lund UniversityCompletedIntravenous Drug Abuse, S Aureus Colonization
-
Duke UniversityCompletedHealth Behavior | Opioid Use, Unspecified | Benzodiazepine Abuse | Prescription Drug Abuse (Not Dependent) | Benzodiazepine Dependent | Prescription Drug Abuse and DependencyUnited States
-
Stuart WillickSports Medicine Research and Testing Laboratory; Partnership for Clean CompetitionCompletedSports Drug Abuse | Abuse of Steroids or HormonesUnited States
-
University of Colorado, DenverCompletedMedication AbuseUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
-
Hasselt UniversityZiekenhuis Oost-Limburg; CAD LimburgCompleted
-
University of CopenhagenActive, not recruitingSports Drug AbuseDenmark
-
Columbia UniversityNational Institute on Drug Abuse (NIDA)CompletedDrug Abuse PreventionUnited States
-
Association Athletes For TransparencyPartnership for Clean Competition; University of Milan School of Medicine; Centre... and other collaboratorsUnknown
-
Boston UniversityNational Institute on Drug Abuse (NIDA)WithdrawnIntravenous Drug Abuse